Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2013, 6(4), 440-468; doi:10.3390/ph6040440
Review

Design of siRNA Therapeutics from the Molecular Scale

,
,
 and *
Received: 24 January 2013; in revised form: 27 February 2013 / Accepted: 13 March 2013 / Published: 25 March 2013
(This article belongs to the Special Issue RNAi-Based Therapeutics)
View Full-Text   |   Download PDF [679 KB, uploaded 25 March 2013]   |   Browse Figures
Abstract: While protein-based therapeutics is well-established in the market, development of nucleic acid therapeutics has lagged. Short interfering RNAs (siRNAs) represent an exciting new direction for the pharmaceutical industry. These small, chemically synthesized RNAs can knock down the expression of target genes through the use of a native eukaryotic pathway called RNA interference (RNAi). Though siRNAs are routinely used in research studies of eukaryotic biological processes, transitioning the technology to the clinic has proven challenging. Early efforts to design an siRNA therapeutic have demonstrated the difficulties in generating a highly-active siRNA with good specificity and a delivery vehicle that can protect the siRNA as it is transported to a specific tissue. In this review article, we discuss design considerations for siRNA therapeutics, identifying criteria for choosing therapeutic targets, producing highly-active siRNA sequences, and designing an optimized delivery vehicle. Taken together, these design considerations provide logical guidelines for generating novel siRNA therapeutics.
Keywords: siRNA therapeutic; RNAi; liver cancer; siRNA design; delivery vehicle design siRNA therapeutic; RNAi; liver cancer; siRNA design; delivery vehicle design
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Angart, P.; Vocelle, D.; Chan, C.; Walton, S.P. Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals 2013, 6, 440-468.

AMA Style

Angart P, Vocelle D, Chan C, Walton SP. Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals. 2013; 6(4):440-468.

Chicago/Turabian Style

Angart, Phillip; Vocelle, Daniel; Chan, Christina; Walton, S. P. 2013. "Design of siRNA Therapeutics from the Molecular Scale." Pharmaceuticals 6, no. 4: 440-468.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert